AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V
-The transaction reflects a pre-money equity value of $400 million for AUM Biosciences -Transaction is expected to provide $69 million of gross proceeds (assuming no redemptions by Mountain Crest stockholders) -Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined market opportunity of $10+ billion in metastatic colorectal cancer, […]
Continue Reading